Birchview Capital, LP Sarepta Therapeutics, Inc. Transaction History
Birchview Capital, LP
- $117 Million
- Q4 2024
A detailed history of Birchview Capital, LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 3,500 shares of SRPT stock, worth $373,625. This represents 0.36% of its overall portfolio holdings.
Number of Shares
3,500
Previous 2,500
40.0%
Holding current value
$373,625
Previous $312,000
36.22%
% of portfolio
0.36%
Previous 0.29%
Shares
2 transactions
Others Institutions Holding SRPT
# of Institutions
535Shares Held
87.4MCall Options Held
1.55MPut Options Held
1.35M-
Black Rock Inc. New York, NY10.3MShares$1.1 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$970 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA8.7MShares$928 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X04.33MShares$462 Million0.28% of portfolio
-
State Street Corp Boston, MA4.07MShares$434 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.35B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...